Clinical Trials
7 trialsNCT07618923 2026-06-01
TD-DASHER-01
Tang-Du Hospital
Phase 2 Not yet recruiting
NCT07539753 2026-04-30
Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT07307287 2025-12-29
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07101159 2025-08-03
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06810492 2025-03-17
The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment
Hubei Cancer Hospital
Phase NA Not yet recruiting
NCT06613373 2024-09-25
An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer
Jiangsu Famous Medical Technology Co., Ltd.
Phase 4 Not yet recruiting
NCT06605690 2024-09-20
An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer
The Affiliated Hospital Of Guizhou Medical University
Phase NA Not yet recruiting